Clinical Trial Update: Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sipuleucel-T with or without tasquinimod in metastatic hormone-resistant prostate cancer has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Tasquinimod (tasquinimod)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-05-20